Cmic Holdings Stock Fair Value – CMIC and DNP Partner to Enhance Healthcare Delivery and Quality
April 29, 2023
Trending News 🌥️
CMIC HOLDINGS ($TSE:2309) Co., Ltd. is a leading player in the Japanese healthcare and pharmaceutical services market. Through their partnership with DNP, they are aiming to further enhance the delivery and quality of healthcare for individuals across Japan. The collaboration brings together the respective strengths of both companies, allowing them to generate more value in the healthcare sector. CMIC HOLDINGS has an extensive track record of success in helping to develop innovative solutions for the healthcare industry. Their expertise spans from the management of clinical drug trials to the facilitation of drug registration. CMIC HOLDINGS also offers a range of services in the pharmaceutical and medical device industries, such as quality assurance and marketing operations. The newly formed partnership between CMIC HOLDINGS and DNP is set to bring together the respective expertise of both companies to create a comprehensive package of health solutions.
These solutions aim to improve quality of care and reduce costs, while providing greater access to healthcare services. The collaboration also seeks to promote better education and research, as well as developing new technology to further enhance healthcare delivery. CMIC HOLDINGS and DNP are confident that their combined knowledge and experience in the healthcare sector will prove beneficial to the people of Japan. By utilizing their collective resources, they are confident that new technologies and services can be developed that will not only improve the quality of care but also reduce costs. The partnership will ensure that the Japanese people have access to the best that modern healthcare has to offer.
Market Price
On Friday, CMIC HOLDINGS announced a strategic partnership with Japanese firm DNP to further enhance healthcare delivery and quality in Japan. According to Tokyo Stock Exchange data, CMIC HOLDINGS stock opened at JP¥1944.0 and ended the day at JP¥1942.0, up by 0.2% from the prior closing price of JP¥1938.0. The partnership is expected to advance healthcare and medical technology through joint research and development of new products, services, and solutions for medical care and healthcare in Japan. The company has established a comprehensive business model that covers research, development, manufacturing, sales, and marketing of pharmaceuticals, medical devices and other healthcare-related products.
With its diverse portfolio, CMIC HOLDINGS is poised to meet the needs of a rapidly aging population in Japan. By combining CMIC HOLDINGS’ expertise in drug development and manufacturing with DNP’s experience in data analytics and artificial intelligence, the partnership is expected to lead to the development of innovative solutions that will help improve patient outcomes and quality of life. The joint venture is expected to bring together the best of both companies, resulting in better healthcare delivery and quality for all Japanese citizens. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cmic Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 113.51k | 8.23k | 8.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cmic Holdings. More…
| Operations | Investing | Financing |
| 11.21k | -8.04k | -1.23k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cmic Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 112.19k | 69.58k | 1.86k |
Key Ratios Snapshot
Some of the financial key ratios for Cmic Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.9% | 42.9% | 10.7% |
| FCF Margin | ROE | ROA |
| 3.4% | 23.6% | 6.8% |
Analysis – Cmic Holdings Stock Fair Value
At GoodWhale, we have conducted an analysis of CMIC HOLDINGS‘s financials and have come up with a fair value for their share. Our proprietary Valuation Line shows that the fair value of CMIC HOLDINGS share is around JP¥1996.9. This is a great opportunity for investors to capitalize on the undervaluation and buy in at the current price. More…
Peers
The competition between CMIC HOLDINGS Co Ltd and its competitors is fierce. IQVIA Holdings Inc, Syneos Health Inc, and Pharmigene Inc are all vying for a piece of the market share in the pharmaceutical and biotechnology industries. With each company offering unique services and products, the competition to stay ahead of the curve is intense. As the industry continues to evolve, the competition between these four companies will only become more fierce.
– IQVIA Holdings Inc ($NYSE:IQV)
IQVIA Holdings Inc is a global healthcare solutions company that provides integrated information and technology-enabled solutions to the world’s healthcare and life sciences industries. With a market cap of 40.03B as of 2023, IQVIA is one of the largest companies in the sector. Their Return on Equity (ROE) of 21.52% is impressive and shows that the company has a strong ability to generate profit from its investments. The company works to optimize and accelerate the development of new treatments and improve the health of patients around the world.
– Syneos Health Inc ($NASDAQ:SYNH)
Synos Health Inc is a leading global biopharmaceutical solutions company. It provides comprehensive clinical and commercial services to biopharmaceutical and medical device companies of all sizes, including large, midsize, and small companies. With a market cap of 3.64B as of 2023 and a Return on Equity of 8.7%, Syneos Health Inc is well-positioned to continue its impressive growth trajectory. The company’s comprehensive offerings help clients bring therapies and products to market faster and more efficiently, giving them an edge over their competition.
– Pharmigene Inc ($TPEX:7595)
Pharmigene Inc is a biotechnology company that specializes in developing treatments for rare and orphan diseases. The company has a market cap of 888.86 million dollars as of 2023 and a Return on Equity of -6.26%. The market cap is an indication of the size of the company and its value in the market, while the Return on Equity is a measure of the company’s efficiency in generating profits from its shareholders’ investments. Despite its negative ROE, Pharmigene Inc still remains a viable investment for those looking for cutting-edge treatments for rare and orphan diseases.
Summary
CMIC HOLDINGS, a leading provider of healthcare services in Japan, has announced a new value creation initiative for healthcare. As part of this plan, DNP and CMIC have agreed to collaborate to develop new products and services in areas such as healthcare IT, medical innovation, and digital health. Through this partnership, DNP and CMIC seek to drive growth and create value in the healthcare sector by leveraging their respective strengths and capabilities. The collaboration will also help CMIC’s business diversification efforts, allowing it to expand its presence in other healthcare-related fields.
This strategic move is expected to benefit both companies, enabling them to capture additional market share and driving further growth and profitability. Investors are advised to keep an eye on this partnership as it could be an important source of long-term value creation.
